**INTRODUCTION:** Recent changes in US healthcare policy have focused on reducing postoperative complications and readmission rates. Understanding risk factors associated with complications may reduce re-admissions and improve clinical outcomes. Previous readmission studies have investigated the NSQIP database, but are limited to 30 days follow-up. In this study, we tracked all immediate breast reconstruction patients for readmissions during the first postoperative year.

**MATERIALS AND METHODS:** After IRB approval, breast reconstruction patients (2010--2012) with minimum of 1-year of follow-up were evaluated. Demographic data, comorbidities, complications, and readmission rates for \<30 days, 31--90 days, and 91 days to 1 year, and non-admission emergency room (ER) visits for the first postoperative year were analyzed. Statistical analysis was performed using a Generalized mixed linear effect model.

**RESULTS:** 353 patients were included in our cohort. Readmission rates were 9.35% for \<30 days, 10.76% for 31--90 days, and 20.12% for 91 days to 1 year. 30 day readmission rates were correlated with surgical site infection (SSI) (OR=11.67, P\<0.001), seroma (OR=5.44, P=0.0007), preoperative bra size of D or greater (OR=3.47, P=0.015), and BMI \> 30 (OR=2.23, P=0.041). 31--90 day readmission rates were significantly increased by SSI (OR=5.48, P= 0.003), implant infection (OR=7.48, P\<0.001), BMI \> 30 (OR=2.19, P= 0.024), and preoperative bra size of D or greater (OR=2.87, P= 0.015). Finally, 91 day to 1 year readmissions were linked to cancer stage 3/4 (OR=2.1, P= 0.013), SSI (OR=4.6, P= 0.008), and implant infection (OR=63.36, P= 0.004). SSI and preoperative bra size of D or greater were significant risk factors for ER visits.

**CONCLUSIONS:** This study addresses the short follow-up of NSQIP readmissions studies, which may not capture late wound healing/infectious complications or the effects of adjuvant breast cancer therapy. The independent risks factors identified may improve risk stratification thus potentially improving clinical outcomes in immediate breast reconstruction.
